Caribou Biosciences Announces Expansion of Scientific Advisory Board

Cells

The CRISPR twins: bioethics for the gene-editing age

Horizon Discovery extends CRISPR Screening Service to primary human T cells

Gene editing

Home » Emerging technologies » Gene editing

Editas Medicine Announces Chief Executive Officer Transition

Katrine Bosley to Step Down as President and CEO Director Cynthia Collins to Serve as Interim CEO Board of Directors Initiates Search for Permanent Successor CAMBRIDGE, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) —...

CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies

Yield10 Bioscience Reports Encouraging Results from 2018 Field Tests of C3003 and Announces Advancement of C3003 into Commercial Development for Canola

WOBURN, Mass., Jan. 15, 2019 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield that enhance global food security...

Precision BioSciences Announces Formation of Scientific Advisory Board With Anderson, Kantarjian, Schinazi and Turtle

eGenesis Appoints Industry Veteran Paul Sekhri as President and Chief Executive Officer

Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies

Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics

inscripta

CRISPR is stuck, and this company can fix it

inscripta

In the First Year of Release, Inscripta’s MAD7 CRISPR Enzyme is Widely Adopted by the Gene-Editing Community

Precision BioSciences and Durham STEM Students Lead Launch of First Genome Editing Experiment Into Space

Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population

Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy

ERS Genomics

ERS Genomics Licenses CRISPR Gene Editing Technology to DefiniGEN to Develop Human Cell Models to Support the Preclinical Development of Therapeutics

U.S. Patent Office Grants Second Charpentier/Doudna Patent Covering CRISPR/Cas9 Gene Editing

News Digest #246 – Synthego raises $110M, the new culture of responsibility, and re-awakening the ag microbiome